Salivary gland infection is one of the most common medical condition across the globe. These infections are mostly caused due to bacteria or viruses. Salivary gland infection affects salivary duct or gland.
Increasing prevalence of various salivary gland infections, changing disease patterns, and environmental changes are major drivers for the market growth. Rising funding for R&D and clinical trials are leading to improved product development is another key factor for market growth. Improved hygiene practices, growing awareness about self-care and advanced diagnosis and treatment options are important driving forces for the market.
The global salivary gland infection market is growing at the CAGR of ~6.7% during the forecast period and expected to reach US$ 3622.6 million by 2023.
Segments:
Global salivary gland infection market has been segmented on the basis of diagnosis which comprises of Plain radiography, sialography, high-resolution ultrasonography, Computed tomography (CT), Magnetic Resonance Imaging (MRI), radionuclide scintigraphy, and others. Sialography is further sub-segmented into CT sialography (ultrafast technique), fluoroscopic/conventional sialography (with or without digital subtraction), and MR sialography.
On the basis of treatment, the market has been segmented into medication, surgery, aspiration, home care, and others. Medication is further sub-segmented into antibiotics and others. Antibiotics are further sub-segmented into dicloxacillin, cephalosporins, clindamycin, and others. Surgery includes removal of part of the parotid salivary gland, removal of all of the parotid salivary gland, removal of the submandibular salivary gland, and others. Home remedies include increased water intake, rest, refraining from smoking, massaging the gland with heat, and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
Key Players for global salivary gland infection market:
Some of the key players in this market are: AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), FUJIFILM Holdings Corporation (Japan), General Electric Company (US), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc.(US), Siemens Healthcare GmbH (Germany), and others